Nanoform Finland

Historical price data

Nanoform Finland is a publicly-traded biotech company with a mission to transform drug delivery through its proprietary nanoforming technology, CESS®. The company has established itself as a key B2B service provider and technology licensor to major pharmaceutical firms, addressing the pervasive industry challenge of poor drug solubility. Its strategy focuses on leveraging a scalable, green chemistry platform to support partners from early development through commercial supply, with recent expansion into high-value biologics and peptides, including GLP-1 agonists. Nanoform's achievements include building a robust pipeline of partnered programs and securing GMP-certified manufacturing capabilities.

Proprietary CESS® (Controlled Expansion of Supercritical Solutions) technology, a scalable, solvent-free process using supercritical CO2 to produce uniform nano-sized particles of drug substances, enhancing solubility and enabling novel delivery routes for both small molecules and biologics.

Nanoform competes with large CDMOs (e.g., Lonza, Catalent) and drug delivery technology firms in the bioavailability enhancement space. Its key differentiators are its proprietary, green CESS® technology, its applicability to both small molecules and biologics, and its integrated end-to-end service model from development to GMP manufacturing.